Navigation Links
Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
Date:10/7/2008

udy's primary endpoint-was clinically and statistically significant (2.5 to 3.6 vs. 1.0; p = 0.0036 to <0.0001). In addition, abdominal pain was clinically and statistically significantly reduced in all linaclotide treatment groups compared to placebo (-0.7 to -0.9 change from baseline on a 5-point ordinal severity scale vs. -0.5; p = 0.0239 to <0.0001) and, in the 26 percent of patients with severe/very severe baseline abdominal pain, improvement was even more pronounced (-0.8 to -1.3 v -0.2; p = 0.0236 to <0.0001). Results for spontaneous bowel movement (SBM) frequency, stool consistency, straining, abdominal discomfort, bloating, IBS symptom severity, and global assessments were statistically significant for the 300 ug and 600 ug dose groups and for at least one of the two lower doses for each endpoint. Treatment effects of linaclotide were rapid in onset (within the first week of treatment) and were maintained throughout the entire 12-week treatment period; there was no indication of rebound clinical effects following cessation of treatment. Linaclotide was well tolerated at all doses with no treatment-related serious adverse events. The most common adverse event was diarrhea; however, there were no associated dehydration or electrolyte abnormalities. Diarrhea resulted in the discontinuation of 1 percent to 7 percent of linaclotide-treated patients and none of the placebo-treated patients.

This study was part of a larger Phase 2 program investigating the effect of linaclotide treatment on patients with IBS-C or chronic constipation (CC). Ironwood and Forest previously announced the results from the Phase 2b CC study and have initiated two pivotal Phase 3 CC trials and expect to initiate two pivotal Phase 3 IBS-C trials by January 2009.

IBS-C Phase 2b Study Design

This North American-based, randomized, multi-center, double-blind, placebo-controlled, dose-range-finding, parallel-group Phase 2b study was designed to assess the safety, efficacy,
'/>"/>

SOURCE Forest Laboratories, Inc.; Ironwood Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain
2. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
3. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
4. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
5. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
6. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
7. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
8. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
9. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
10. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
11. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Research and Markets ... Chinese Aseptic Packaging Industry Report 2014" report to ... The Global and Chinese Aseptic Packaging Industry ... current state of the global Aseptic Packaging industry with ... provides a basic overview of the industry including definitions, ...
(Date:7/30/2014)... N.J. , July 30, 2014  InnoPharma, Inc. ... Injection, 10mg/vial (the generic equivalent of Zyprexa® injection), in ... agitation and disturbed behaviors in patients with schizophrenia or ... this generic injectable drug, InnoPharma has entered into an ... Sandoz Canada will make, use, sell, market and ...
(Date:7/30/2014)... YORK and KISSING, Germany ... and distributor of a single use and computer-assisted ("robotic") ... (Homi) Shamir , a worldwide recognized medical device executive, ... Mr. Shamir is a highly respected global ... recent assignment he served as President and Chief Executive ...
Breaking Medicine Technology:Global and Chinese Aseptic Packaging Industry Report 2014 2InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3
... Okla., March 9, 2011 Sandra Smith filed suit today ... over a failed hip replacement system from Johnson & Johnson, ... market.  John David Hart of the Law Offices of John ... Ms. Smith. Smith, of Yukon, underwent surgeries ...
... Inc. (NYSE: WST ) today announced that management ... Miami, FL.  Management will present an overview of West,s business ... ET. A live audio webcast of the Company,s ... will be accessible from the Company,s website at www.westpharma.com/en/investors ...
Cached Medicine Technology:Woman Files Suit in Federal Court Against DePuy Orthopaedics, Inc.,/Johnson & Johnson Over Recalled Hip Device 2
(Date:7/30/2014)... that could help doctors decide which bladder cancer patients ... effective, according to a study* published in the ... from The University of Manchester, funded by the Medical ... high levels of a protein, called ,HIF-1α, were more ... with carbon dioxide gas and nicotinamide tablets at ...
(Date:7/30/2014)... CA (July 30, 2014) With the advent of ... a popular science and researchers must work to ... study of stroke rehabilitation. A new study out ... systematic shift in perspective and suggests that chronically ... strongly promote stroke motor recovery, for example by ...
(Date:7/30/2014)... percent of Parkinson,s disease (PD) patients and their ... challenge: the occurrence of impulse control disorders (ICDs) ... spending. Yet the presence of PD in these ... A team of investigators from the Perelman School ... the Parkinson,s Disease Research, Education and Clinical Center ...
(Date:7/30/2014)... Europe commercial aviation actuation system market is estimated at ... reach $1,686.72 million by 2019 at a CAGR of ... of opportunities and challenges which will assume prominence in ... in the past, yet the sector has regained quickly, ... growth rate of approximately 5 % per year. Despite ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Bringing Disney ... September event hosted by the Central Iowa Chapter of ... Institute is bringing its renowned professional development course, “Disney’s ... 16, 2014. The full-day world class workshop will inspire ... business results, retain employees and satisfy customers. , “Disney ...
Breaking Medicine News(10 mins):Health News:Scientists pinpoint bladder cancer patients who could benefit from 'tumor-softening' treatment 2Health News:Neuro researchers advocate for a shift in thinking for stroke rehabilitation 2Health News:Penn researchers: Naltrexone may diminish impulse control disorders in Parkinson's disease patients 2Health News:Europe Aviation Actuation System Market is Expected to Reach $1,686.72 Million in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Aviation Actuation System Market is Expected to Reach $1,686.72 Million in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Aviation Actuation System Market is Expected to Reach $1,686.72 Million in 2019 - New Report by MicroMarket Monitor 4Health News:Central Iowa Chapter of ATD Hosts Exclusive Disney Institute for Central Iowa Businesses 2Health News:Central Iowa Chapter of ATD Hosts Exclusive Disney Institute for Central Iowa Businesses 3
... CHICAGO, June 17 Continuing its efforts to educate, inform, ... not-for-profit patient-focused organization, is hosting its 25-minute live call-in show, ... June 22, 2009 at 6:00 PM on Channel 21. ... discussion with Deborah Harper Brown, Clinical Pharmacist, who will inform ...
... Registration is underway for the CPAP SUCCESS GROUP being held at ... Monday, July 6 at 4PM at 541 Main Street in the ... designed to help struggling CPAP users become better accustomed to CPAP ... and effectively by learning simple relaxation techniques that promote breathing normally ...
... release of the IntelliFlowRx workflow management system provides ... , ENGLEWOOD, Colo., June 17 Baxa Corporation ... workflow management system. IntelliFlowRx is designed to ... preparation. The system also streamlines compliance with ...
... gene, variant ups violence inclination, study finds , WEDNESDAY, June 17 ... blamed for boys joining violent street gangs. But a new study ... in part, in their genes. , Boys who have a variant ... the "warrior gene" -- are not only more likely to be ...
... , - SLA Centennial Observance ... Century , Elsevier has been awarded ... BioMedicine and the Life Sciences" at the Special Library,Association,s (SLA) ... published by Elsevier, many on behalf of renowned,societies, were also ...
... Recognizes Entrepreneurial Excellence in Health and Life Sciences Category , ... -- Accuray Incorporated (Nasdaq: ARAY ), a ... Euan Thomson, Ph.D., the company,s president and CEO, received the ... the Health and Life Sciences category in Northern California. ...
Cached Medicine News:Health News:The Consumer's Role in Medication Safety -- An Interactive Discussion with a Pharmacist on Live TV 2Health News:Help for Struggling CPAP Users Comes to Sleep HealthCenters in Weymouth 2Health News:Baxa Corporation Releases IntelliFlowRx(TM) Upgrades 2Health News:Boys May Feel a Genetic Pull Toward Gangs 2Health News:Elsevier Honored as "The Most Influential Publisher of the Last 100 Years in BioMedicine and the Life Sciences" by the Special Libraries Association 2Health News:Elsevier Honored as "The Most Influential Publisher of the Last 100 Years in BioMedicine and the Life Sciences" by the Special Libraries Association 3Health News:Elsevier Honored as "The Most Influential Publisher of the Last 100 Years in BioMedicine and the Life Sciences" by the Special Libraries Association 4Health News:Accuray's Euan Thomson Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Recipient in Northern California 2Health News:Accuray's Euan Thomson Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Recipient in Northern California 3
... quality patient care., ,S/5 Anesthesia Delivery ... anesthesia delivery. As part of the S/5 ... electronically controlled gas delivery and agent vaporization ... create a truly integrated system. The S/5 ...
... filler and Tegagel hydrogel wound filler ... specially formulated to help provide a ... to enhance wound healing. The unique, ... for management of non-draining, minimally draining ...
... SS is a complete physician preference card ... management system for all the supply management ... preference card system combined with a broad ... entire case cart and operating suite supply ...
Easy to Use manual vacuum system features a pumping mechanism that can be operated with one hand....
Medicine Products: